Profile data is unavailable for this security.
About the company
Ocean Biomedical Holdings, Inc., formerly Ocean Biomedical, Inc., is a United States-based biopharmaceutical company. The Company is focused on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases and inflammation. In oncology, it is developing a mono-specific and two bi-specific humanized monoclonal antibodies (mAb), product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer (NSCLC) and glioblastoma multiforme (GBM). In fibrosis, it is developing a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS). It has three product candidates: a malaria vaccine candidate targeting either or both of Plasmodium falciparum schizont egress antigen (PfSEA-1), and parasite antigen Plasmodium falciparum glutamic-acid-rich protein(PfGARP); a humanized mAb malaria therapeutic candidate targeting PfGARP; and a small molecule malaria therapeutic candidate.
- Revenue in USD (TTM)0.00
- Net income in USD-98.59m
- Incorporated2021
- Employees9.00
- LocationOcean Biomedical Inc55 Claverick Street, Room 212PROVIDENCE 02903United StatesUSA
- Phone+1 (401) 444-7375
- Fax+1 (302) 655-5049
- Websitehttps://www.oceanbiomedical.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Surrozen Inc | 0.00 | -37.58m | 35.15m | 42.00 | -- | 0.7684 | -- | -- | -18.44 | -18.44 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -67.75 | -- | -77.52 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -19.55 | -- | -- | -- |
IN8BIO, Inc. | 0.00 | -31.04m | 35.23m | 31.00 | -- | 1.97 | -- | -- | -0.9154 | -0.9154 | 0.00 | 0.4049 | 0.00 | -- | -- | 0.00 | -123.61 | -74.18 | -145.63 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0556 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
Mink Therapeutics Inc | 0.00 | -20.59m | 35.49m | 31.00 | -- | -- | -- | -- | -0.5964 | -0.5964 | 0.00 | -0.585 | 0.00 | -- | -- | 0.00 | -175.32 | -- | -3,661.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 19.77 | -- | -- | -- |
Carmell Corp | 0.00 | -18.29m | 36.22m | 9.00 | -- | -- | -- | -- | -1.58 | -1.49 | 0.00 | -0.0719 | 0.00 | -- | -- | 0.00 | -428.46 | -- | -- | -- | 58.60 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -75.70 | -- | -- | -- |
Curis Inc | 9.81m | -47.73m | 36.84m | 48.00 | -- | 3.89 | -- | 3.75 | -8.68 | -8.68 | 1.77 | 1.61 | 0.1253 | -- | 4.39 | 204,416.70 | -60.97 | -37.25 | -69.58 | -41.12 | 97.60 | 96.05 | -486.45 | -409.44 | -- | -- | 0.00 | -- | -1.37 | -0.7891 | 16.34 | -- | -- | -- |
Aeon Biopharma Inc | 0.00 | -485.01m | 37.58m | 10.00 | -- | -- | -- | -- | -13.04 | -13.04 | 0.00 | -5.20 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -27.67 | -- | -- | -- | -- | -631.85 | -- | -- | -- |
Angion Biomedica Corp | 0.00 | -38.99m | 37.79m | 32.00 | -- | 7.72 | -- | -- | -6.63 | -6.63 | 0.00 | 0.4765 | 0.00 | -- | -- | 0.00 | -117.72 | -105.91 | -133.85 | -331.69 | -- | -- | -- | -712.81 | -- | -- | 0.00 | -- | -100.00 | -- | 9.31 | -- | -- | -- |
Atara Biotherapeutics Inc | 34.70m | -233.11m | 37.81m | 173.00 | -- | -- | -- | 1.09 | -52.93 | -52.93 | 7.54 | -20.43 | 0.1485 | 0.9947 | 1.92 | 154,240.00 | -99.76 | -70.20 | -213.09 | -86.94 | 69.30 | -- | -671.70 | -1,559.33 | 0.50 | -- | -- | -- | -86.51 | -- | -20.95 | -- | -49.14 | -- |
Akari Therapeutics PLC (ADR) | -100.00bn | -100.00bn | 38.03m | 9.00 | -- | -- | -- | -- | -- | -- | -- | -0.4449 | -- | -- | -- | -- | -- | -149.95 | -- | -435.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 43.61 | -- | -- | -- |
Ocean Biomedical Holdings Inc | 0.00 | -45.58m | 38.11m | 9.00 | -- | -- | -- | -- | -1.40 | -1.40 | 0.00 | -0.0642 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -612.50 | -- | -- | -- |
Vaxxinity Inc | 0.00 | -56.94m | 39.30m | 57.00 | -- | 2.93 | -- | -- | -0.4499 | -0.4499 | 0.00 | 0.1058 | 0.00 | -- | -- | 0.00 | -75.56 | -- | -111.46 | -- | -- | -- | -- | -- | -- | -- | 0.5308 | -- | -- | -- | 24.31 | -- | -- | -- |
DURECT Corp | 8.32m | -23.28m | 39.73m | 48.00 | -- | 4.79 | -- | 4.77 | -0.8653 | -0.8653 | 0.2976 | 0.2674 | 0.176 | 0.7021 | 6.87 | 143,465.50 | -49.23 | -37.34 | -167.81 | -53.44 | 80.56 | 91.83 | -279.77 | -139.11 | 0.9575 | -47.70 | 0.6377 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
Matinas BioPharma Holdings Inc | 0.00 | -23.25m | 40.18m | 32.00 | -- | 2.39 | -- | -- | -0.107 | -0.107 | 0.00 | 0.0669 | 0.00 | -- | -- | 0.00 | -80.36 | -44.62 | -86.16 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.0014 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
BioXcel Therapeutics Inc | 1.76m | -153.05m | 40.53m | 74.00 | -- | -- | -- | 23.08 | -5.18 | -5.18 | 0.0591 | -2.15 | 0.0134 | 0.6067 | 5.31 | 23,729.73 | -116.64 | -74.57 | -151.39 | -84.06 | 24.15 | -- | -8,715.72 | -32,300.74 | 2.49 | -15.67 | 3.47 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
OncoCyte Corp | 1.38m | -40.66m | 40.90m | 43.00 | -- | 2.18 | -- | 29.59 | -4.94 | -4.94 | 0.1682 | 2.05 | 0.018 | -- | 1.34 | 32,139.54 | -51.95 | -35.11 | -58.73 | -39.71 | 22.07 | -- | -2,890.23 | -2,373.36 | -- | -157.69 | 0.00 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
Estrella Immunopharma Inc | 0.00 | -2.16m | 41.65m | -- | -- | 4.00 | -- | -- | -1.90 | -1.90 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -5.92 | -- | -7.86 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -302.11 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Polar Asset Management Partners, Inc.as of 31 Mar 2024 | 2.69m | 7.76% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 432.79k | 1.25% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 259.96k | 0.75% |
OMERS Administration Corp.as of 31 Mar 2024 | 245.40k | 0.71% |
Geode Capital Management LLCas of 31 Mar 2024 | 233.45k | 0.67% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 136.31k | 0.39% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 80.76k | 0.23% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 63.03k | 0.18% |
AllianceBernstein LPas of 31 Mar 2024 | 55.08k | 0.16% |
LPL Financial LLCas of 31 Mar 2024 | 30.00k | 0.09% |